SCHEMBL1546970

SCHEMBL1546970

COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4C(F)(F)F)cc3Cl)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.86

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AXL P30530 20/20 0.86
EGFR P00533 4/20 0.86
MET P08581 4/20 0.86
SRC P12931 4/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546789 0.93 AXL (1.00) AXLEGFRMETSRC
SCHEMBL1547063 0.93 AXL (1.00) AXLEGFRMETSRC
SCHEMBL1554785 0.91 AXL (0.88) AXLEGFRMETSRC
SCHEMBL1546665 0.89 AXL (0.81) AXLEGFRMETSRC
SCHEMBL1556013 0.87 AXL (0.91) AXLEGFRMETSRC
SCHEMBL1546932 0.87 AXL (1.00) AXLEGFRMETSRC
SCHEMBL1546663 0.87 AXL (1.00) AXLEGFRMETSRC
SCHEMBL1555888 0.87 AXL (0.88) AXLEGFRMETSRC
SCHEMBL1555029 0.87 AXL (0.88) AXLEGFRMETSRC
SCHEMBL1555915 0.86 AXL (0.88) AXLEGFRMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP claimed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US claimed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US claimed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US claimed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 EP claimed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO claimed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP claimed
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP disclosed
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US disclosed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 EP disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO disclosed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP disclosed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885EGFR 2891/4885MET 2187/4885
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885EGFR 2891/4885MET 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.